Pursuant to the ‘Code of Conduct for Prevention of Insider Trading’ of the Company, SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time read with Bombay Stock Exchange (BSE) Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 regarding trading restriction period and as per Company’s Code of Conduct for prevention of Insider Trading, Triochem Products has informed the Trading window for the dealing in Securities of the Company shall remain closed from Tuesday, 1st October 2024 till 48 hours after the declaration of unaudited financial results of the Company for the quarter and half year ended 30th September 2024 for the all KMP, designated persons, Directors, promoters, persons acting in concert, employees of the Company, along with their respective immediate relatives, person having contractual and fiduciary relation with the Company including but not limited to Auditors, accountancy firm, law firms, analysts, consultants, etc., assisting or advising the Company, shall not involve in any transaction for dealing/trading/pledge in the securities of the Company during the period when Trading Window is closed. Accordingly, it has decided to close the Trading Window from 1st October 2024 till 48 hours after declaration of Unaudited Financial Results of the company for the quarter and half year ended 30th September 2024. The date of the Board Meeting in which results would be considered shall be intimated in due course. During the closure of Trading Window, insiders have been advice not to deal in the shares of the company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1887.95 |
| Dr. Reddys Labs. | 1348.70 |
| Cipla | 1431.65 |
| Zydus Lifesciences | 1149.00 |
| Lupin | 2457.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: